Wedbush Maintains Outperform on Sana Biotechnology, Raises Price Target to $7

Benzinga Newsdesk www.benzinga.com Positive 90.1%

Neg 0% Neu 0% Pos 90.1%

Wedbush analyst Martin Fan maintains Sana Biotechnology (NASDAQ:SANA) with a Outperform and raises the price target from $6 to $7.